INDV – indivior plc (US:NASDAQ)

News

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $15.00.
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Indivior Announces Q3 2024 Financial Results
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com